Compare Avantis International Small Cap Value ETF (AVDV) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis International Small Cap Value ETF vs Sana Biotechnology Inc — how do they compare? Avantis International Small Cap Value ETF trades at $110.2, while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Avantis International Small Cap Value ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| AVDV | SANA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $110.40 | $5.92 |
52-Week Low | $83.89 | $2.68 |
Market Cap | — | $1.13B |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVDV trades at $110.28, up 0.75% today, with a bullish technical signal from moving averages but caution from overbought oscillators. The stock shows strength near resistance at $110, supported by positive media coverage highlighting international small-cap value performance and a forthcoming dividend. Recent news notes a 21% return since November 2025, driven by commodity exposure that has since cooled.
Outlook remains positive due to strong momentum and dividend yield, but risks include overbought conditions and reliance on international markets. Investors should weigh technical indicators against fundamental growth prospects in developed ex-US small caps.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
